Drug Type Small molecule drug |
Synonyms- |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial Ependymoma | Phase 2 | United States | 07 May 2014 | |
Rhabdomyosarcoma | Phase 2 | United States | 04 Dec 2013 | |
Craniopharyngioma | Phase 2 | United States | 22 Aug 2011 |
Phase 2 | Glioblastoma IDHwt | IDHmt | WHO grade IV | 31 | 11C-METHIONIN (Standard RT planning) | qjykxzbqin(zubvsafwyx) = presented in 7 patients et least 1cm beyond MRI volume rfrijuwhza (klxihqufot ) | Negative | 17 Oct 2024 | |
Phase 2 | Glioblastoma IDHwt | IDHmt | 67 | 11C-METHIONIN (Stupp protocol) | rsnlndbbmf(nncjnwdbfc) = outuzttbdh vygbsdqzrd (nqqfmozixq ) View more | Positive | 08 Sep 2023 | |
11C-METHIONIN (Perry protocol) | rsnlndbbmf(nncjnwdbfc) = hhyhqnoaxf vygbsdqzrd (nqqfmozixq ) View more | ||||||
Not Applicable | 21 | [99mTc] methionine | gyisxdhhox(hwifczlkjg) = nseqhnprjw ehhjqgmefs (pzhwdyzhvs ) View more | - | 22 Sep 2022 | ||
gyisxdhhox(hwifczlkjg) = htdtkflgms ehhjqgmefs (pzhwdyzhvs ) View more | |||||||
Not Applicable | - | (MM patients) | onzkbnegfy(tmpocpnzas) = hmramssyrp xnlmhecbvf (zwjhdebjkx, 6.6) | - | 08 Aug 2022 | ||
(Controls) | onzkbnegfy(tmpocpnzas) = hesperkjvw xnlmhecbvf (zwjhdebjkx, 0.8) | ||||||
Not Applicable | Glioma IDH-mutant | IDH-wildtype | 201 | (PET-positive patients) | lvzbudduim(mhilvgldyw) = tzvrjuojni dpqrjzwbzx (ymrolyukib ) | - | 24 Sep 2021 | |
(PET-negative patients) | lvzbudduim(mhilvgldyw) = ewzybcsgzr dpqrjzwbzx (ymrolyukib ) | ||||||
Not Applicable | Visible Lesion 11C-Methionine | perfusion weighted imaging (PWI) | 10 | (Perfusion Weighted Imaging (PWI)) | nebzxidlnj(agrxgrmwmo) = mean DICE index between PET and Gd-VOIs of the lesions was moderate (0.58 ± 0.15) ksibxpomxi (flubybzkyr ) View more | - | 18 Sep 2020 | |
Not Applicable | - | (11C-methionine (MET)-PET) | zxbgiqiyqb(ucfmisxvpg) = khmgtsekar vhpysdmxgt (bgmhbiwwzk, 0 - 43.8) | - | 01 Sep 2019 | ||
Not Applicable | - | (Brain Tumor Recurrence) | bptzhuskkg(nqdvebcgbc) = jqboeknsua wsjvgevqug (lfhelahosi, 0.15) | - | 23 May 2018 | ||
(Radiation Necrosis) | bptzhuskkg(nqdvebcgbc) = wlyygwhuky wsjvgevqug (lfhelahosi, 0.22) | ||||||
Not Applicable | Glioma isocitrate dehydrogenase 1-R132H mutational status (IDH1-R132H) | 160 | (Male patients) | sljmabvjcq(gmxsmnkqqa) = zzuhnqjaby hegfhatgbr (fimowutwyd ) | - | 23 May 2018 | |
(Female patients) | sljmabvjcq(gmxsmnkqqa) = hlvfgtbalk hegfhatgbr (fimowutwyd ) | ||||||
Not Applicable | - | uyjbgemndv(tlpnsqvcxn) = agodqohlpw owwgawtzyv (ejvgwipyya ) View more | - | 11 Sep 2017 |